Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal fibrotic lung disease of unknown cause.¹ The incidence of IPF is increasing and in 2016, 50% survival rates of just 4–5 years were confirmed.² Disease progression is highly variable in individual patients and therefore difficult to predict.³ High mortality plus unpredictability, together with the fact that IPF therapies are costly (antifibrotic drugs) or sparsely available (transplant), highlights the need for better and clinically applicable prognostic tools.

中文翻译：

---

IPF的个性化药物：越来越近，但还没有到那儿

特发性肺纤维化（IPF）是一种原因不明的慢性，进行性和致命性纤维化肺病。¹ IPF的发病率正在上升，2016年，仅4-5年的生存率就被确认为50％。²疾病进展在各个患者中变化很大，因此很难预测。³高死亡率加上不可预测性，再加上IPF疗法昂贵（抗纤维化药物）或稀疏可用（移植）的事实，凸显了对更好和临床适用的预后工具的需求。